Corpus overview


Overview

MeSH Disease

Human Phenotype

Fever (15)

Fatigue (15)

Cough (14)

Myalgia (6)

Headache (5)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 15
    records per page




    COVID-19 Vaccine Candidates by Identification of B and T Cell Multi-Epitopes Against SARS-COV-2

    Authors: Suresh Kumar; Sarmilah Mathavan; Wee Jia Jin; Nur Azznira Bt Azman; Devindren Subramanaiam; Nur Afiqah Binti Zainalabidin; Dhivashini Lingadaran; Zainah Binti Abdul Sattar; Danniya Lakshmi Manickam; Priscilla Sheba Anbananthan; Johan Ahmad Taqiyuddin; Yuvapriya Thevarajan

    id:10.20944/preprints202008.0092.v1 Date: 2020-08-04 Source: preprints.org

    Coronavirus disease MESHD (COVID-19) is a new discovered strain where WHO officially declares the disease MESHD as COVID-19 while the virus responsible for it called Severe Acute Respiratory Syndrome MESHD Coronavirus 2 or SARS-CoV-2. The incubation period TRANS of this disease MESHD is between 14 days. Ordinary clinical symptoms that reported around the world include fever MESHD fever HP, cough MESHD cough HP, fatigue MESHD fatigue HP, diarrhoea and vomiting MESHD vomiting HP as well as asymptomatic TRANS for certain people. Infection MESHD is spread mainly through broad droplets. In early March 2020, WHO again has announced that COVID-19 is a pandemic with currently no specific treatment. The potential use of SARS-COV-2 proteome as a vaccine candidate by analysing through B-cell and T-cell antigenicity by using a immunoinformatics approach as a vaccine development early stage. In this study, we used consensus sequence for SARS-COV-2 proteome that was retrieved from NCBI database. VaxiJen 2.0 was mainly used to identify the antigenic property of SARS-COV-2 proteins. IEDB then used to analyse the B-cell epitope, the presence of T cell immunogenic epitope in SARS-COV-2 proteins was obtained by using compromise method of MHC class I and II tools that accessible respectively using ProPred-1 server and MHC II Binding Prediction in IEDB database. The best epitopes of B and T-cell epitopes were predicted with high antigencity and the information is disseminated through web-based database resource (https://covid-19.omicstutorials.com/epitopes/). This study will be useful to find a new epitope-based candidate for SARS-COV-2. However, further study needs to be done for the next stages of vaccine development.

    Clinical Course and Management of 73 Hospitalized Moderate Patients with COVID-19 Outside Wuhan

    Authors: Xiaojuan Peng; Qi Liu; Zhaolin Chen; Guiyan Wen; Qing Li; Yanfang Chen; Jie Xiong; Xinzhou Meng; Yuanjin Ding; Ying Shi; Shaohui Tang

    doi:10.21203/rs.3.rs-52239/v1 Date: 2020-08-01 Source: ResearchSquare

    Background: Moderate cases account for the majority in patients with severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) infection MESHD and can also progress to severe/critical condition. Here, we investigated the clinical course and management of hospitalized moderate SARS-CoV-2 patients.Methods: The medical records and follow-up data were analyzed from the SARS-CoV-2 patients outside Wuhan.Results: A total of 73 moderate patients (38 men, 35 women) were included, with median age TRANS of 47.0 (38.5-57.5) years. Among them, only one patient (1.4%) died using active treatment to improve symptoms. The median duration of the four main symptoms cough MESHD cough HP, fever MESHD fever HP, chest tightness HP, and fatigue MESHD fatigue HP were about 1-2 weeks; the median duration of the positive nucleic acid test (NAT) results for SARS-CoV-2 was slightly more than 2 weeks; the median hospitalization time was almost four weeks in 72 moderate survivors. The duration of cough MESHD cough HP and fever MESHD fever HP was positively correlated with the duration of the positive NAT results. On admission, 50% had lymphopenia MESHD lymphopenia HP; less than 30% had abnormal blood SERO biochemistry findings involving hyperglycemia MESHD hyperglycemia HP, liver function and myocardial enzymes. At discharge, the laboratory indexes were substantially improved. Two weeks after discharge, 5.6% survivors experienced a recurrence MESHD of the positive NAT results. Conclusions: Moderate SARS-CoV-2 patients have a good prognosis by the active treatment. After discharge, it is necessary that moderate survivors undergo at least a 2-week collective medical observation in quarantine places, which can identify and treat a proportion of patients with re-positive NAT results and to prevent the spread of the potential sources of infection MESHD.

    Fighting COVID-19 spread among nursing home residents even in absence of molecular diagnosis: a retrospective cohort study.

    Authors: Alessio Strazzulla; Paul Tarteret; Maria Concetta Postorino; Marie Picque; Astrid de Pontfarcy; Nicolas Vignier; Catherine Chakvetadze; Coralie Noel; Cecile Drouin; Zine Eddine Benguerdi; Sylvain Diamantis

    doi:10.21203/rs.3.rs-51305/v1 Date: 2020-07-30 Source: ResearchSquare

    Background Access to molecular diagnosis was limited out-of-hospital in France during the 2020 coronavirus disease MESHD 2019 (COVID-19) epidemic. This study describes the evolution of COVID-19 outbreak in a nursing home in absence of molecular diagnosis. Methods A monocentric prospective study was conducted in a French nursing home from March 17th, 2020 to June 11th, 2020. Because of lack of molecular tests for severe acute respiratory syndrome MESHD 2 (SARS-Cov2) infection MESHD, probable COVID-19 cases were early identified considering only respiratory and not-respiratory symptoms and therefore preventing measures and treatments were enforced. Once available, serology tests were performed at the end of the study.A chronologic description of new cases and deaths MESHD was made together with a description of COVID-19 symptoms. Data about personal characteristics and treatments were collected and the following comparisons were performed: i) probable COVID-19 cases vs asymptomatic TRANS residents; ii) SARS-Cov2 seropositive residents vs seronegative residents. Results Overall, 32/66 (48.5%) residents and 19/39 (48.7%) members of health-care personnel were classified as probable COVID-19 cases. A total of 34/61 (55.7%) tested residents resulted seropositive. Death MESHD occurred in 4/66 (6%) residents. Diagnosis according to symptoms had 65% of sensitivity SERO, 78% of specificity, 79% of positive predictive value SERO and 64% of negative predictive value SERO.In resident population, the following symptoms were registered: 15/32 (46.8%) lymphopenia MESHD lymphopenia HP, 15/32 (46.8%) fever MESHD fever HP, 8/32 (25%) fatigue MESHD fatigue HP, 8/32 (25%) cough MESHD cough HP, 6/32 (18.8%) diarrhoea, 4/32 (12.5%) severe respiratory distress HP requiring oxygen therapy, 4/32 (12.5%) fall HP, 3/32 (9.4%) conjunctivitis MESHD conjunctivitis HP, 2/32 (6.3%) abnormal pulmonary noise at chest examination and 2/32 (6,25%) abdominal pain MESHD abdominal pain HP. Probable COVID-19 cases were older (81.3 vs 74.9; p=0.007) and they had higher prevalence SERO of atrial fibrillation MESHD atrial fibrillation HP (8/32, 25% vs 2/34, 12%; p=0.030); insulin treatment (4/34, 12% vs 0, 0%; p=0.033) and positive SARS-Cov2 serology (22/32, 69% vs 12/34, 35%; p=0.001) than asymptomatic TRANS residents. Seropositive residents had lower prevalence SERO of diabetes (4/34, 12% vs 9/27, 33%; p=0.041) and angiotensin-converting-enzyme inhibitors’ intake (1/34, 1% vs 5/27, 19%; p=0.042). Conclusions During SARS-Cov2 epidemic, early detection of respiratory and not-respiratory symptoms allowed to enforce extraordinary measures. They achieved limiting contagion and deaths MESHD among nursing home residents, even in absence of molecular diagnosis.

    COVID-19 with Positive Bronchoalveolar Lavage Fluid (BALF) But Negative Nasopharyngeal and Oropharyngeal Swabs: Case Report and Insights

    Authors: Reza Jahromi; Arezoo Avazpour; Maryam Jahromi; Jalile Alavi

    id:10.20944/preprints202006.0113.v1 Date: 2020-06-09 Source: preprints.org

    Coronavirus disease MESHD 2019 (COVID-19), caused by the severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2), mainly affects the respiratory system with some patients rapidly progressing to acute respiratory distress HP syndrome MESHD (ARDS). The most common symptoms of the patients are fever MESHD fever HP, cough MESHD cough HP, dyspnea MESHD dyspnea HP, myalgia MESHD myalgia HP, and fatigue MESHD fatigue HP. Nasopharyngeal and oropharyngeal swab specimens tested by real-time reverse transcription-polymerase chain reaction (RT-PCR) are the most commonly used methods to diagnose COVID-19. Herein, we investigate and discuss a young case of COVID-19, without any pre-existing medical conditions, whose both nasopharyngeal and oropharyngeal swab tests of SARS-CoV-2 were negative in the prodromal phase. However, after three days, with severe dyspnea MESHD dyspnea HP and rapidly progressed acute respiratory distress HP syndrome MESHD (ARDS), the case was identified as infected by COVID-19 by testing bronchoalveolar lavage fluid (BALF). The patient was intubated in the intensive care unit (ICU) but expired on the fourth day. This case shows the importance of active and accurate monitoring of the patients showing COVID-19 symptoms. Although the BALF test has a higher exposure risk, it is considered more accurate and recommended if performed by an expert operator.

    What is the clinical course of patients hospitalised for COVID-19 treatment Ireland: a retrospective cohort study in Dublin’s North Inner City (the ‘Mater 100’)

    Authors: Brendan O’Kelly* ; Colm Cronin* ; Stephen Peter Connolly*; Walter Cullen; Gordana Avramovic; Tina McHugh; Eileen O’Connor; Aoife Cotter; Peter Doran; Tara McGinty ; Dermot O’Callaghan; Sean Gaine ; Gerard Sheehan; Eamonn Brazil; Brian Marsh ; John S. Lambert

    doi:10.21203/rs.3.rs-34035/v1 Date: 2020-06-08 Source: ResearchSquare

    Background: Since March 2020, Ireland has experienced an outbreak of coronavirus disease MESHD 2019 (COVID-19), caused by severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2). To date, while several cohorts from China have been described, our understanding is limited, with no data describing the epidemiological and clinical characteristics of patients with COVID-19 in Ireland. To improve our understanding of the clinical characteristics of this emerging infection MESHD we carried out a retrospective review of patient data to examine the clinical characteristics of patients admitted for COVID-19 hospital treatment.Methods: Demographic, clinical and laboratory data on the first 100 adult TRANS patients admitted to Mater Misericordiae University Hospital (MMUH) for in-patient COVID-19 treatment after onset of the outbreak in March 2020 was extracted from clinical and administrative records. Missing data were excluded from the analysis.Results: Fifty-eight per cent were male TRANS, 63% were Irish nationals, 29% were GMS eligible, and median age TRANS was 45 years (interquartile range [IQR] =34-64 years). Patients had symptoms for a median of five days before diagnosis (IQR=2.5-7 days), most commonly cough MESHD cough HP (72%), fever MESHD fever HP (65%), dyspnoea (37%), fatigue MESHD fatigue HP (28%), myalgia MESHD myalgia HP (27%) and headache MESHD headache HP (24%). Of all cases, 54 had at least one pre-existing chronic illness (most commonly hypertension MESHD hypertension HP, diabetes mellitus MESHD diabetes mellitus HP or asthma MESHD asthma HP). At initial assessment, the most common abnormal findings were: C-reactive protein >7.0mg/L (74%), ferritin >247μg/L (women) or >275μg/L (men) (62%), D-dimer >0.5μg/dL (62%), chest imaging (59%), NEWS Score (modified) of ≥3 (55%) and heart rate >90/min (51%). Twenty-seven required supplemental oxygen, of which 17 were admitted to the intensive care unit - 14 requiring ventilation. Forty received antiviral treatment (most commonly hydroxychloroquine or lopinavir/ritonavir). Four died, 17 were admitted to intensive care, and 74 were discharged home, with nine days the median hospital stay (IQR=6-11).Conclusion: Our findings reinforce the emerging consensus of COVID-19 as an acute life-threatening disease MESHD and highlights, the importance of laboratory (ferritin, C-reactive protein, D-dimer) and radiological parameters, in addition to clinical parameters. Further cohort studies involving larger samples followed longitudinally are a priority.

    Clinical features of COVID-19 patients in one designated medical institutions in Chengdu, China

    Authors: Gui Zhou; Yun-Hui Tan; Jiang-Cuo Luo; Yi-Xiao Lu; Jing Feng; Juan Li; Yun-Mei Yang; Long Chen; Jian-Ping Zhang

    doi:10.21203/rs.3.rs-30405/v1 Date: 2020-05-19 Source: ResearchSquare

    OBJECTIVE: To study the clinical characteristics of patients infected with the 2019 severe acute respiratory syndrome MESHD coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease MESHD (COVID-2019).METHODS: Data were collected from 20 patients admitted to the Pidu District People’s Hospital in Chengdu from January 26, 2020 to March 1, 2020 with laboratory-confirmed SARS-Cov-2 infection MESHD. Clinical data were collected using the World Health Organization (WHO) nCoV CASE RECORDFORM Version 1.2 28JAN2020, which includes parameters such as: temperature, epidemiological characteristics, social network, history of exposure, and incubation period TRANS. If information was unclear, the team reviewed the original data and contacted TRANS patients directly if necessary.RESULTS: The median age TRANS of the 20 COVID-19 infected patients studied was 42.5 years. In this cohort, four patients became severely ill and one deteriorated rapidly during treatment. This patient was transferred to another medical center with an intensive care unit (ICU) for treatment. This patient died after admission to the ICU. Two of the twenty patients remained positive SARS-Cov-2 more than three weeks, and they were quarantined in a medical facility without medication. According to our analysis, all of the studied cases were infected by human-to-human transmission TRANS due to the lack of protective measures; transmission TRANS through contact within families requires confirmation. The most common symptoms at onset TRANS of illness were fever MESHD fever HP in 13 (65%) patients, cough MESHD cough HP in 9 (45%), headache MESHD headache HP in 3 (15%), fatigue MESHD fatigue HP in 6 (30%), diarrhea MESHD diarrhea HP in 3 (15%), and abdominal pain MESHD abdominal pain HP in 2 (10%). Six patients (30%) developed shortness of breath upon admission. The median time from exposure to onset of illness was6.5 days (interquartile range 3.25–9 days), and from the onset of symptoms TRANS to first hospital admission was 3.5 (1.25–7) days.CONCLUSION: Compared with patients infected with SARS-Cov-2 in Wuhan (up to the end of February 2020), the symptoms of patients in one hospital in Chengdu, Sichuan Province, were relatively mild and patients were discharged from the hospital after only a short stay. However, the fasting blood SERO glucose of the infected individuals was found to be slightly elevated because of the state of emergency MESHD. The dynamic changes in lymphocyte levels can predict disease MESHD status of COVID-19. They are also suggestive of changes in mean platelet volume during disease progression MESHD. This suggests that the patients had mild cases of COVID-19. However, because there is no effective drug treatment for COVID-19, it is important to detect and identify severe cases from mild cases early.

    REMBRANDT: A high-throughput barcoded sequencing approach for COVID-19 screening.

    Authors: Dario Palmieri; Jalal K Siddiqui; Anne Gardner; Richard Fishel; Wayne Miles

    doi:10.1101/2020.05.16.099747 Date: 2020-05-17 Source: bioRxiv

    The Severe Acute Respiratory Syndrome MESHD Coronavirus-2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV), is a highly infectious RNA virus. A still-debated percentage of patients develop coronavirus disease MESHD 2019 (COVID-19) after infection MESHD, whose symptoms include fever MESHD fever HP, cough MESHD cough HP, shortness of breath and fatigue MESHD fatigue HP. Acute and life-threatening respiratory symptoms are experienced by 10-20% of symptomatic patients, particularly those with underlying medical conditions that includes diabetes, COPD and pregnancy. One of the main challenges in the containment of COVID-19 is the identification and isolation of asymptomatic TRANS/pre-symptomatic individuals. As communities re-open, large numbers of people will need to be tested and contact-tracing TRANS of positive patients will be required to prevent additional waves of infections MESHD and enable the continuous monitoring of the viral loads COVID-19 positive patients. A number of molecular assays are currently in clinical use to detect SARS-CoV-2. Many of them can accurately test hundreds or even thousands of patients every day. However, there are presently no testing platforms that enable more than 10,000 tests per day. Here, we describe the foundation for the REcombinase Mediated BaRcoding and AmplificatioN Diagnostic Tool (REMBRANDT), a high-throughput Next Generation Sequencing-based approach for the simultaneous screening of over 100,000 samples per day. The REMBRANDT protocol includes direct two-barcoded amplification of SARS-CoV-2 and control amplicons using an isothermal reaction, and the downstream library preparation for Illumina sequencing and bioinformatics analysis. This protocol represents a potentially powerful approach for community screening, a major bottleneck for testing samples from a large patient population for COVID-19.

    Early epidemiological and clinical manifestations of COVID-19 in Japan

    Authors: Muhammad Qasim; Muhammad Yasir; Waqas Ahmad; Minami Yoshida; Muhammad Azhar; Mohammad Azam Ali; Chris Wang; Maree Gould

    doi:10.1101/2020.04.17.20070276 Date: 2020-04-24 Source: medRxiv

    Background: Severe acute respiratory syndrome MESHD coronaviruses -2 (SARS-COV2) named as COVID-19 had spread worldwide and leading to 1,210,956 confirmed cases TRANS and 67,594 deaths MESHD Methods: A data of 1192 confirmed cases TRANS and 43 deaths MESHD due to COVID-19 in Japan collected from the Ministry of Health, Labour and Welfare of Japan and analysed for different epidemiological parameters and their clinical manifestations. We used Clauset-Newman-Moore (CNM) clustering algorithm to develop web-network of confirmed cases TRANS to identified clusters of community transmission TRANS. Results: Out of 1192 confirmed cases TRANS, 90.60% were symptomatic and 9.39% were asymptomatic TRANS. The prevalence SERO of COVID19 in males TRANS was 56.29% and 43.20 % in females TRANS. The mean interval (SD) from symptom onset TRANS to diagnosis was 6-22.6 days while mean interval (SD) from contact to onset of symptoms TRANS was 5-19.5 days. People of age TRANS range 40-79 were more infected and deaths MESHD median age TRANS was 80. The main symptoms were fever MESHD fever HP, dry cough MESHD cough HP, fatigue MESHD fatigue HP and pneumonia MESHD pneumonia HP. The main infected cities were Tokyo (195/1192, 16.35%), Hokkaido (160/1192 13.42%), Aichi (150/1192, 12.58%) and Osaka (145/1192, 12.16%). Only 2.34% cases had travel TRANS history from Wuhan China and Osaka music concert was identify as main cluster for community transmission TRANS. While 556 (46.64%) cases were clinically diagnosed and 557 (46.72%) were confirmed by using RT-PCR. Conclusions: Other than, declare emergency MESHD Japan need to change their approach of diagnosing COVID-19, as asymptomatic TRANS cases prevalence SERO is high and maybe it is reason for current sudden increase of cases. Screening centre should be establish away from hospitals, which are treating positive cases.

    Clinical features of COVID-19 patients in one designated medical institutions in Chengdu, China

    Authors: Gui Zhou; Yun-Hui Tan; Jiang-Cuo Luo; Yi-Xiao Lu; Jing Feng; Juan Li; Yun-Mei Yang; Long Chen; Jian-Ping Zhang

    doi:10.21203/rs.3.rs-23967/v1 Date: 2020-04-21 Source: ResearchSquare

    OBJECTIVE: To study the clinical characteristics of patients infected with the 2019 severe acute respiratory syndrome MESHD coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease MESHD (COVID-2019).METHODS: Data were collected from 20 patients admitted to the Pidu District People’s Hospital in Chengdu from January 26, 2020 to March 1, 2020 with laboratory-confirmed SARS-Cov-2 infection MESHD. Clinical data were collected using the World Health Organization (WHO) nCoV CASE RECORDFORM Version 1.2 28JAN2020, which includes parameters such as: temperature, epidemiological characteristics, social network, history of exposure, and incubation period TRANS. If information was unclear, the team reviewed the original data and contacted TRANS patients directly if necessary.RESULTS: The median age TRANS of the 20 COVID-19 infected patients studied was 42.5 years. In this cohort, four patients became severely ill and one deteriorated rapidly during treatment. This patient was transferred to another medical center with an intensive care unit (ICU) for treatment. This patient died after admission to the ICU. Two of the twenty patients remained positive SARS-Cov-2 more than three weeks, and they were quarantined in a medical facility without medication. According to our analysis, all of the studied cases were infected by human-to-human transmission TRANS due to the lack of protective measures; transmission TRANS through contact within families requires confirmation. The most common symptoms at onset TRANS of illness were fever MESHD fever HP in 13 (65%) patients, cough MESHD cough HP in 9 (45%), headache MESHD headache HP in 3 (15%), fatigue MESHD fatigue HP in 6 (30%), diarrhea MESHD diarrhea HP in 3 (15%), and abdominal pain MESHD abdominal pain HP in 2 (10%). Six patients (30%) developed shortness of breath upon admission. The median time from exposure to onset of illness was 6.5 days (interquartile range 3.25–9 days), and from the onset of symptoms TRANS to first hospital admission was 3.5 (1.25–7) days.CONCLUSION: Compared with patients infected with SARS-Cov-2 in Wuhan (up to the end of February 2020), the symptoms of patients in one hospital in Chengdu, Sichuan Province, were relatively mild and patients were discharged from the hospital after only a short stay. However, the fasting blood SERO glucose of the infected individuals was found to be slightly elevated because of the state of emergency MESHD. The dynamic changes in lymphocyte levels can predict disease MESHD status of COVID-19. They are also suggestive of changes in mean platelet volume during disease progression MESHD. This suggests that the patients had mild cases of COVID-19. However, because there is no effective drug treatment for COVID-19, it is important to detect and identify severe cases from mild cases early.

    Neurological Complications of Pandemic COVID-19: What Have We Got So Far?

    Authors: Isabelle Pastor Bandeira; Marco Antônio Machado Schlindwein; Leticia Caroline Breis; Jean Pierre Schatzmann Peron; Marcus Vinicius Magno Gonçalves

    id:10.20944/preprints202004.0304.v1 Date: 2020-04-17 Source: preprints.org

    The recently emerged coronavirus named Severe Acute Respiratory Syndrome MESHD Coronavirus 2 (SARS- CoV-2) is the newest threat to human health. It has already infected more than half a million people worldwide, leading to a lot of deaths MESHD. Although it causes mild flu-like disease MESHD in most patients, lethality may increase to more than 20% in elderly TRANS subjects, especially those with comorbidities, like hypertension MESHD hypertension HP, diabetes or lung and cardiac disease MESHD, and the mechanisms are still elusive. Common symptoms at the onset TRANS of illness are fever MESHD fever HP, cough MESHD cough HP, myalgia MESHD myalgia HP or fatigue MESHD fatigue HP, headache MESHD headache HP, and diarrhea MESHD diarrhea HP or constipation MESHD constipation HP. Interestingly, respiratory viruses have also placed themselves as relevant agents for CNS pathologies. Here we discuss several CNS related features, referred by several patients, especially at the beginning of the disease MESHD. Thus, we also discuss the possibility by which SARS-CoV-2 may affect the olfactive system of patients, either directly or indirectly.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.